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ABSTRACT
Haploidentical transplantation is a feasible alternative for patients with life-threatening hematologic diseases
who lack a matched donor. Factors affecting the clinical outcomes of haploidentical transplantation remain
under investigation. We analyzed 157 consecutive patients with leukemia who underwent transplantation
with nonmanipulated granulocyte colony-stimulating factor (G-CSF)-mobilized marrow and peripheral blood
cells (G-BMPBs) from haploidentical donors after receiving myeloablative chemotherapy (Ara-C 1 BuCy 1
antithymocyte globulin). Follow up observations after transplantation weremade from 48 days to 1191 days (me-
dian, 448 days). Multivariate analysis indicated that the cohort given higher doses of CD31 cells ($ 177106 /kg)
in allograft transplantation had a significantly lower treatment-related mortality (TRM) (relative risk [RR] 5
0.35; 95% CI 5 0.16-0.77; P 5 .0090), better leukemia-free survival (LFS) (RR 5 0.46; 95% CI 5 0.26-0.84;
P 5 .0106), and better overall survival (OS) (RR 5 0.42; 95% CI 5 0.23-0.78; P 5 .0058). Inversely, advanced-
stage disease was a strong predictor of greater posttransplantation relapse (RR 5 3.48; 95% CI 5 1.26- 9.60;
P 5 .0159), worse LFS (RR 5 2.56; 95% CI 5 1.33-4.95; P 5 .0050), and worse OS (RR 5 2.77; 95% CI 5
1.39-5.53; P 5 .0038). A high number of CD31 cells (. 177  106/kg) given to patients resulted in statistically
less TRM and more intensive graft versus leukemia effect without producing more severe grades of GVHD, all
resulting in a significantly better overall clinical outcome from haploidentical transplantation.
 2007 American Society for Blood and Marrow Transplantation
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Since 1956, when a graft-versus-tumor (GVT) ef-
fect was first observed in irradiated mice receiving allo-
geneic but not syngeneic marrow transplants [1], the
concept of allogeneic hematopoietic cell transplanta-
tion (HCT) as a form of immunotherapy has been
well accepted [2]. The dramatic effect of allogeneic he-
matopoietic stem cell transplantation (HSCT) demon-
strates the ability of donor lymphohematopoietic cells
to successfully repopulate treated recipient marrow,
making the eradication of certain malignancies possi-
ble. Maintaining a stable hematopoietic/immunologicreconstitution in recipients of HCT and also inducing
a considerable GVT effect requires relatively large
numbers of donor lymphohematopoietic cells. Previ-
ous studies have shown that transplantation of a high
dose of marrow cells is associated with reduced treat-
ment-related mortality (TRM) and improved survival
and results in improved short-term and long-term
graft function [3,4]. The doses of CD31 [5], CD81
[6], and CD341 cells [7-9] may be critical for success-
ful engraftment in a selective CD341 cell transplanta-
tion setting. To date, however, a clear association of
those T cell subsets with the clinical outcomes1515
1516 L. Dong et al.remains uncertain; some results are even controversial
[6,7-10]. Currently, no data are available on the proper
or optimal cell dose of nonmanipulated granulocyte
colony-stimulating factor (G-CSF)-mobilized marrow
and peripheral blood cells (G-BMPBs) in transplanta-
tion after a conditioning regimen that includes antithy-
mocyte globulin (ATG). Such studies of graft
constituents are drawing increasing attention, not
only because these infused cells play a crucial role
in hematopoietic/immune reconstitution after trans-
plantation, but also because determination of cell
dose is one of the few manageable (or controllable)
pretransplantation factors [11,12]. Family HLA-
mismatched/haploidentical transplantation offers a
feasible therapeutic approach to patients with lethal
malignant hematologic diseases without an HLA-
matched donor, a situation that is becoming more
common as family size shrinks. An earlier study from
our center showed that patients with advanced-stage
disease and no family or unrelated HLA-matched
donor might achieve nearly comparable therapeutic
effects from a family mismatched/haploidentical
transplantation [13]. Since then, more patients, in-
cluding those with early-stage disease with high-risk
prognostic features, have been enrolled. The cell
subpopulations in the donor grafts and the clinical
pretransplantation factors of the patients in this study
were all carefully evaluated.
METHODS
Data Collection and Patient Selection
A total of 157 consecutive patients who underwent
haploidentical transplantation between January 25,
2002, and March 31, 2005, at Peking University
Institute of Hematology and Dao-Pei Hospital were
enrolled. Only patients with a diagnosis of acute mye-
logenous leukemia (AML), acute lymphoblastic leuke-
mia (ALL), chronic myelogenous leukemia (CML), or
myelodysplastic syndrome (MDS) and no HLA-
matched related or unrelated donors were eligible for
the study. The following criteria for disease stage
were used:
 Early stage: CML in chronic phase (CP); AML or
ALL in first remission (CR1)
 Intermediate stage: CML in accelerated phase (AP);
AML or ALL in second remission (CR2); MDS with
severe refractory anemia and thrombocytopenia
 Advanced stage: advanced or resistant AML or ALL;
MDS-refractory anemia with excess blasts or MDS-
AML; CML in blast phase (BP).
The complete immune phenotype was deter-
mined for cell populations in each graft. The age
range for patients was 6–50 years (median, 25 years),
and that for donors was 13–66 years (median, 40
years) (Table 1). A total of 78 patients with early-stage disease were enrolled because most of them
had unfavorable prognostic features. The protocol
[13] was reviewed and approved by the Institutional
Review Board (IRB) at Peking University Institute
of Hematology. All patients or their guardians were
required to sign consent forms approved by the
IRB. Detailed patient and donor characteristics are
given in Table 1.
Donor Source and HLA Disparity
Family members were tested for HLA compatibil-
ity using serology and intermediate-resolution DNA
typing for HLA-A, -B, and -C antigens and high-
resolution DNA typing for HLA-DRB1, -DQB1,
and -DPB1. Donors were patients’ mothers in 65
cases (41.4%), fathers in 25 cases (16%), cousins in
4 cases (2.5%), siblings in 48 cases (30.6%), and chil-
dren in 15 cases (9.5%), with various degrees of HLA
disparity in HLA-A, -B, and -DRB1 antigen levels
(Tables 1 and 2).
Graft Collection and Cell Composition Analysis
Donor BM and/or PB cells were collected using
modified mobilization protocols; subcutaneous G-
CSF (filgrastim) 5 mg/kg/day was given from day 23
Table 1. Clinical data
Number of patients 157
Patient age, median (range), years 25 (6-50)
Donor age, median (range), years 40 (13-66)
Donor–patient sex match, n (%)
Female to male 26 (17%)
Others 131 (83%)
Donor–patient relationship, n (%)
Sibling 48 (31%)
Mother to child 65 (41%)
Others 44 (28%)









Number of HLA-antigen mismatches, n (%)
1 Ag 27 (17%)
2 Ag 71 (45%)
3 Ag 59 (38%)
Graft type, n (%)
BM 1 PB 156 (99.4%)
PB alone 1 (0.6%)
MNCs, median (range), 108/kg 7.3 (4.2-16.3)
CD341 count, median (range), 106/kg 2.3 (0.5-9.7)
CD31 count, median (range), 106/kg 177 (15-991)
CD41 count, median (range), 106/kg 100 (13-527)
CD81 count, median (range), 106/kg 74 (15-467)
Follow-up time among living patients,
median (range), days
448 (48-1191)
CD31 Cell Dose and Disease Status after Haploidentical HCT 1517Table 2. Patient and donor characteristics according to CD31 cell dose
Variable CD31\ 177106/kg CD31 $ 177106/kg P
Number of patients 78 79
Recipient age, median (range), years 24 (6-50) 25 (7-50) .95
\ 20 26 (33%) 28 (35%) .98
20-35 30 (38%) 31 (39%)
35-50 21 (27%) 19 (24%)
$ 50 1 (1%) 1 (1%)
Donor age, median (range), years 40 (14-58) 40 (13-66) .29
\ 20 6 (8%) 8 (10%) .51
20-35 11 (14%) 14 (18%)
35-50 42 (54%) 45 (57%)
$ 50 19 (24%) 12 (15%)
Donor–patient sex matching .08
M to M 20 (26%) 25 (32%)
M to F 35 (45%) 21 (27%)
F to F 9 (12%) 17 (21%)
F to M 14 (18%) 16 (20%)
Donor–patient relationship .04
Mother to child 38 (49%) 27 (34%)
Father to child 8 (10%) 17 (22%)
Cousin 4 (5%) 0
Sibling 21 (27%) 27 (34%)
Child to parent 7 (9%) 8 (10%)
Blood match .15
Matched 43 (55%) 38 (48%)
Minor ABO incompatibility 18 (23%) 13 (17%)
Major ABO incompatibility 17 (22%) 28 (35%)
HLA-antigen class mismatches .52
Class I (HLA-A and/or HLA-B) 15 (19%) 16 (20%)
Class II (HLA-DRB1) 5 (7%) 9 (12%)
Class I and II 58 (74%) 54 (68%)
Number of HLA-antigen mismatches .41
1 Ag 11 (14%) 16 (20%)
2 Ag 39 (50%) 32 (41%)
3 Ag 28 (36%) 31 (39%)
Disease .09
CML 30 (38%) 22 (28%)
AML 24 (31%) 17 (21%)
ALL 20 (26%) 34 (43%)
MDS 4 (5%) 6 (8%)
Disease status .94
Early 39 (50%) 39 (49%)
Intermediate 19 (24%) 18 (23%)
Advanced 20 (26%) 22 (28%)
MNCs, median (range), 108/kg 6.8 (4.2-12.1) 7.8 (4.2-16.3) \ .0001
\ 7.5 55 (71%) 31 (39%) \ .0001
$ 7.5 23 (29%) 48 (61%)
CD341, median (range), 106/kg 1.9 (0.5-7.1) 2.3 (0.5-9.7) .17
\ 2 41 (53%) 28 (35%) .03
$ 2 37 (47%) 51 (65%)
CD41, median (range), 106/kg 69 (17-373) 131 (13-527) \ .0001
\ 100 65 (83%) 13 (16%) \ .0001
$ 100 13 (17%) 66 (84%)
CD81, median (range), 106/kg 49 (15-312) 103 (25-467) \ .0001
\ 75 61 (78%) 19 (24%) \ .0001
$ 75 17 (22%) 60 (76%)
Follow-up among survival patients, median (range), days n 5 50 n 5 63
414 (48-1150) 514 (113-1191) .03to day 0. BM was harvested at day 0, after 4 days of G-
CSF administration, with a target collection dose of 15
mL/kg (recipient weight), and PB, harvested on day 1,
5 days after the first G-CSF injection. The grafts were
analyzed for the total number of mononuclear cells(MNCs), and, using a standardized Multi-Set kit (Bec-
ton-Dickinson, San Jose, CA), the content of CD341
cells [14] and subsets of lymphoid cell populations
(CD31, CD41, and CD81 cells) was determined (Ta-
bles 1 and 2).
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All patients enrolled in this study were treated un-
der a uniform protocol with the conditioning regimen
(Ara-C1 Bu/Cy1ATG) [13] and GVHD prophylaxis
(cyclosporine [CsA] 1 short-term methotrexate
[MTX] [15,16] 1 mycophenolate mofetil [MMF]).
Pretransplantation conditioning chemotherapy in-
cluded cytarabine 4 g/m2/day intravenously on days
210 to –9, Bu 4 mg/kg/d orally on days 28 to –6,
Cy 1.8 g/m2/day intravenously on days 25 and 24,
Me-CCNU 250 mg/m2 orally once on day 23, and
ATG (thymoglobuline; Sang Stat, Lyon, France,
now marketed by Genzyme) 2.5 mg/kg/day intrave-
nously on days 25 to 22. First-line therapy for $
grade II GVHD was 1-2 mg/kg/day of prednisolone
equivalents and resumption of full-dose cyclosporine
(CSP). Patients who developed steroid-refractory
acute GVHD (aGVHD) were given tacrolimus
(FK506), MMF, CD25 monoclonal antibody (Simu-
lect, Novartis), or MTX as second-line immunosup-
pressive therapy.
Definition of Endpoints
The study endpoints were engraftment, grade II-
IV or III-IV aGVHD, TRM, relapse, leukemia-free
survival (LFS), and overall survival (OS).
Neutrophil Engraftment. Neutrophil engraft-
ment after transplantation was defined as a recovery
of the blood absolute neutrophil count (ANC) to $
0.5  109/L on 3 consecutive days. Platelet recovery
was defined as the time after transplantation needed
to maintain a blood platelet count $ 20 109/L with-
out transfusion support for 7 consecutive days.
GVHD. aGHVD and chronic GVHD (cGVHD)
were defined according to Fred Hutchinson Cancer
Research Center criteria [17-19]. Patients who sur-
vived for . 100 days after transplantation were evalu-
ated for cGVHD.
Relapse. Time to relapse was defined from the date
of transplantation to the date of disease recurrence,
evaluated by morphological evidence of leukemia in
either the BM or any extramedullary site.
TRM. TRM was defined as all causes of death other
than those related directly to malignant disease itself,
occurring at any time after transplantation.
OS and LFS. OS was defined as days from trans-
plantation to death from any cause. LFS was defined
as days from transplantation to disease progression
after transplantation.
Statistical Analysis
The characteristics of patient-related, disease-
related, and transplantation-related factors of the low
and high CD31 cell dose groups were compared using
the c2 test for categorical variables and the Mann-
Whitney test for continuous variables. Univariateprobabilities of achieving ANC and platelet engraft-
ment, developing aGVHD and cGVHD, TRM, and
relapse were calculated using cumulative incidence
curves to accommodate corresponding competing
risks. The Kaplan-Meier estimator was used to evalu-
ate LFS and OS. Comparing the outcomes among
CD31 cell dose groups required adjustment for differ-
ences in baseline patient characteristics (Table 2). A
Cox proportional hazards model was used to adjust
for potential imbalance in baseline characteristics be-
tween CD31 cell dose groups. Outcome events con-
sidered in multivariate analyses were TRM, relapse,
treatment failure (opposite of LFS), and overall mor-
tality (opposite of OS). A forward stepwise method
was used to identify all significant risk factors for
each outcome event. The effect of the dose of CD31
cells transplanted (the main interest in the present
study) was included in all steps of model building.
The proportionality assumptions were tested by add-
ing a time-dependent covariate; the tests indicated
that the proportionality assumptions held for all risk
factors. The potential interactions between main treat-
ment groups and significant risk factors were tested,
and no interactions were found (Table 3) Adjusted
Table 3. Multivariate analysis of association with TRM, relapse, LFS,
and OS




$ 177 0.35 (0.16-0.77) .0090
Relapse
CD31:\ 177 1.00
$ 177 0.72 (0.29-1.79) .4778
Other covariates
Disease status: Early 1.00 .0263*
Intermediate 1.02 (0.25-4.06) .9835




$ 177 0.46 (0.26-0.84) .0106
Other covariates
Disease status: Early 1.00 .0175*
Intermediate 1.40 (0.67-2.93) .3760




$ 177 0.42 (0.23-0.78) .0058
Other covariates
Disease status: Early 1.00 .0136*
Intermediate 1.46 (0.67-3.18) .3398
Advanced 2.77 (1.39-5.53) .0038
Relapse: P 5 .0617 for intermediate versus advanced disease.
Treatment failure: P 5 .1025 for intermediate versus advanced
disease.
Overall mortality: P 5 .0975 for intermediate versus advanced
disease.
*2 degree-of-freedom test.
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final Cox models stratified on treatment; weighted
averages of covariate values were computed using the
sample proportion as the weight function. These ad-
justed probabilities estimated the likelihood of out-
comes in populations with similar prognostic factors.
To examine the aGVHD effect, a time-dependent co-
variate was used in the final Cox regression models
(Table 4). Finally, the cell dose effects of MNCs,
CD341, CD41, and CD81 were evaluated using the
Cox regression method (Table 5).
RESULTS
Characteristics of Patients Receiving a Low or High
CD31 Cell Dose
The median CD31 cell number in the transplant
inoculums was 177 106/kg (range, 15-991 106/
kg). Patients were stratified into 2 cohorts; 1 cohort
was given a lower than median dose of CD31 cells
(\ 177  106/kg [n 5 78]), and the other was given
a greater than median or median dose of CD31 cells
($ 177  106/kg [n 5 79]). The differences in clinical
characteristics between the 2 cohorts were not statisti-
cally significant; the patients in the high-dose CD31
cell cohort were infused with significantly higher num-
bers of MNCs, CD341, CD41, and CD81 cells than
those in the low-dose CD31 cell cohort (Table 2).
Neutrophil and Platelet Recovery
All patients in the study achieved complete granu-
locyte engraftment, as reflected by the ANC attained.
The median time after transplant to achieve an ANC
of $ 0.5  109/L was 12 days (range, 8-25 days); the
median time to achieve a blood platelet count of
$ 20  109/L was 15 days (range, 7-169 days) in all
but 5 patients. Three of these 5 patients had died
from nonrelapse-related mortality (NRM) at day 36-
84 posttransplantation. Two were alive; 1 survived to
399 days, the other to 206 days. The cumulative inci-
dence of platelet engraftment was 97% (95% confi-
dence interval [CI] 5 94%-100%) in the low CD31
Table 4. Effect of aGVHD on clinical endpoints
Outcome RR (95% CI) P
TRM
aGVHD: III-IV versus 0-II 3.16 (1.43-6.99) .0046
Relapse
aGVHD: III-IV versus 0-II 1.34 (0.38-4.73) .6524
Treatment failure
(Opposite of LFS)
aGVHD: III-IV versus 0-II 2.32 (1.18-4.57) .0150
Overall mortality
(Opposite of OS)
aGVHD: III-IV versus 0-II 2.64 (1.29-5.43) .0082
Effect of aGVHD is treated as a time-dependent covariate.cell dose cohort (\ 177  106/kg) versus 95% (95%
CI 5 89%-98%) in the high CD31 cell dose cohort
($ 177 106/kg) (P5 .3626). There was no significant
difference in the cumulative incidence of ANC and
platelet engraftment between the 2 CD31 cell dose co-
horts (Figures 1A and B).
GVHD
High CD31 cell dose ($ 177 106/kg) transplan-
tation correlated with a higher incidence of grade II-
IV aGVHD, 51% (95% CI 5 40%-61%), compared
with low CD31 cell dose (\ 177  106/kg) transplan-
tations, 39% (95% CI5 28%-49%), but the difference
was not statistically different (P 5 .1165) (Figure 1C).
No significant difference was found in the cumulative
incidence of grade III-IV aGVHD between the high
CD31 cell cohort, 19% (95% CI 5 11%-28%), and
the low CD31 cell cohort, 15% (95% CI 5 8%-
24%), (P 5 0.5449) (Figure 1D). In the 157 patients
evaluated, the cumulative incidence of cGVHD at 2
years was 44% (95% CI 5 32%-55%) in the low
CD31 cell dose cohort and 52% (95% CI 5 41%-
63%), in the high CD31 cell dose cohort
(P 5 .3100).
Death
Relapse. Patients undergoing transplantations
containing high CD31 cell doses ($ 177  106
CD31 cells/kg) had fewer relapses at 2 years, 12%
Table 5. Effect of MNC, CD341, CD41, and CD81 levels on clinical
endpoints
Outcome RR (95% CI) P
TRM
MNCs: $ 7.5 vs\ 7.5108/kg 0.70 (0.33-1.49) .3586
CD341: $ 2 vs\ 2 106/kg 0.67 (0.33-1.40) .2874
CD41: $ 100 vs\ 100106/kg 0.62 (0.30-1.31) .2099
CD81: $ 75 vs\ 75 106/kg 0.73 (0.35-1.53) .4090
Relapse
MNCs: $ 7.5 vs\ 7.5 108/kg 2.52 (0.95-4.68) .0632
CD341: $ 2 vs\ 2 106/kg 2.58 (0.85-7.80) .0941
CD41: $ 100 vs\ 100106/kg 1.33 (0.53-3.33) .5384
CD81: $ 75 vs\ 75106/kg 1.40 (0.56-3.51) .4694
Treatment failure
(Opposite of LFS)
MNCs: $ 7.5 vs\ 7.5 108/kg 1.11 (0.62-1.96) .7316
CD341: $ 2 vs\ 2 106/kg 1.04 (0.58-1.86) .8956
CD41: $ 100 vs\ 100 106/kg 0.83 (0.47-1.46) .5151
CD81: $ 75 vs\ 75 106/kg 0.97 (0.54-1.73) .9161
Overall mortality
(Opposite of OS)
MNCs: $ 7.5 vs\ 7.5108/kg 0.97 (0.53-1.76) .9065
CD341: $ 2 vs\ 2 106/kg 0.96 (0.52-1.75) .8816
CD41: $ 100 vs\ 100 106/kg 0.80 (0.44-1.45) .4537
CD81: $ 75 vs\ 75 106/kg 1.05 (0.58-1.91) .8762
Effects are examined based on final regression models for TRM,
relapse, treatment failure, and overall mortality (see Table 3).
1520 L. Dong et al.Figure 1. Cumulative incidence of outcomes of haploidentical HCT for patients with leukemia. A, ANC (P5 1.0000 at day
100). B, Platelet engraftment (P5 .3626 at day 100). C, aGVHD, grade 2-4 (P5 .1165 at day 100). D, aGVHD, grade 3-4
(P 5 .5449 at day 100). E, Relapse (P 5 .3962 at 2 years). F, TRM (P 5 .0181 at 2 years).(95% CI 5 6%-21%), than in the cohort receiving
low CD31 cell doses (\ 177  106 CD31 cells/
kg), 18% (95% CI 5 8%-31%), but the difference
was not statistically significant (P 5 .3962)
(Figure 1E). Thirteen patients died from disease re-
lapse between 36 and 945 days after transplantation
with various coexisting complications: severe infection,
43%; grade III-IV aGVHD, 35.7%; and interstitialpneumonia (IPn), 50%; along with varying grades of
aGVHD.
TRM. A total of 31 patients died from various com-
plications between 72 and 590 days after transplanta-
tion: 27.3% from Ipn, 30.3% from lung infection
due to mixed pathogens; 57.6% from nonpulmonary
infection, and 24.2% from severe (grade 3-4) aGVHD.
In patients whose grafts included high CD31 cell
CD31 Cell Dose and Disease Status after Haploidentical HCT 1521doses ($ 177 106/kg), the 2-year TRM of 13% (95%
CI 5 6%-22%) was statistically lower than the 30%
(95% CI 5 19%-41%) in those whose grafts contained
fewer CD31 cells (\ 177  106/kg) (P 5 .0181)
(Figure 1F).
Survival
Follow-up of surviving patients from 48 to 1191
days posttransplantation (median, 448 days) revealed
a 53% (95% CI 5 39%-66%) probability of 2-year
LFS for patients with grafts containing fewer CD31
cells (\ 177  106/kg) and a 75% (95% CI 5 64%-
84%) probability of 2–year LFS in those with grafts
containing more CD31 cells ($ 177  106/kg)
(P5 .0115) (Figure 2A). OS after haploidentical trans-
plantation in the cohort was 70.2%. Univariate analysis
demonstrated that only disease status and CD31 cell
dose in the graft were important predictors of survival.
The 2-year probability of survival was 77% in those
who underwent transplantation in the early stage of dis-
ease, 57% in those who did so in the intermediate stage,
and 48% in those who did so in an advanced stage.
There was no statistical difference in survival probabil-
ity between those with intermediate-stage disease and
advanced disease (log-rank test; P 5 .3246); however,
a significant difference in survival probability was
seen between patients who underwent transplantation
in early-stage disease (77%; 95% CI 5 66%-86%)
and those who did so in intermediate-stage or advanced
disease (56%; 95% CI 5 43%-68%) (P 5 .0052). In
addition, the probability of 2-year survival in the cohort
undergoing transplantation with a low CD31 cell dose
(\ 177  106/kg), 52% (95% CI 5 37%-67%), was
lower than that seen in the cohort who underwent
transplantation with a high CD31 cell dose ($ 177 
106/kg), 77% (95% CI 5 66%-86%) (P 5 .0075)
(Figure 2B).Multivariate Analysis
Variables considered in the multivariate analyses
were patient age group (\ 20, 20-34, $ 35 years), do-
nor–patient sex match, donor type (sibling vs others),
number of HLA antigen mismatches, disease type, dis-
ease stage, graft type, CMV, MNCs ($ 7.5 vs\7.5 
108/kg), CD341 ($ 2 vs\2  106/kg), CD31 ($ 177
vs\177 106/kg), CD41 ($ 100 vs\100 106/kg),
and CD81 ($ 75 vs\75 106/kg). Multivariate anal-
ysis (Table 3) showed that advanced-stage disease at
the time of transplantation was associated with a worse
LFS (2.56; 95% CI5 1.33-4.95; P5 .0050). Inversely,
a high dose of CD31 cells in the graft was associated
with better LFS (0.46; 95% CI 5 0.26-0.84; P 5
.0106) (Table 3). The disease status before transplanta-
tion and CD31 cell dose given also had a significant
influence on OS. Advanced-stage disease predicted
a worse outcome (relative risk [RR] 5 2.77; 95% CI
5 1.39-5.53; P 5 .0038). However, patients had a sig-
nificantly better survival if the transplant contained
a high CD31 cell dose, $ 177  106/kg (RR 5 0.42;
95% CI 5 0.23-0.78; P 5 .0058) (Table 3). Donor–
recipient pair relationships showed no significant ef-
fect on outcomes.
Grades III-IV aGVHD posttransplantation had
a significant effect on the various endpoint outcomes
measured (Table 4). However, cGVHD had no obvi-
ous impact on these endpoints—a finding that could
change with a longer follow-up time. Univariate and
multivariate analysis showed that the numbers of
MNCs, CD341, CD41, or CD81 cells in the trans-
plants had no significant influence on these clinical
endpoints (Table 5).
DISCUSSION
The present study is the largest study to date eval-
uating the predictors of developing GVHD, TRM,Figure 2. Adjusted probabilities of LFS and OS after haploidentical HCT for patients with leukemia (adjusted for early,
intermediate, and advanced disease status). A, Adjusted probability of LFS (P5 .0115 at 2 years). B, Adjusted probability of
OS (P 5 .0075 at 2 years).
1522 L. Dong et al.relapse, and survival in patients who, after receiving an
identical conditioning regimen, (including ATG), un-
derwent transplantation with unmanipulated nucle-
ated cells from haploidentical blood and marrow
donors. Stable engraftment and long-term survival af-
ter family mismatched/haploidentical HCT likely in-
volves multiple mechanisms such as the conditioning
regimen [11,12], inherited maternal/paternal antigen
(NIMA/NIPA) mismatch existing in donor-recipient
pairs [20,21], disease status [22,23], donor versus recip-
ient natural killer cell alloreactivity [23,24], and the
number of CD341 cells infused [8,11,23]. Previous
reports were based mainly on the results of CD341
cell selected transplantation, which involved marked
T-cell depletion in vitro. Thus, the CD31 cell doses
given in those studies were very low, ranging from
103/kg to 105/kg of recipients’ body weight
[8,11,25,26]. Including ATG in the pretransplantation
conditioning regimen provides an effective means of
depleting T cells in vivo and preventing severe
GVHD. But intensive T cell depletion in vivo by
ATG also can delay immune reconstitution, resulting
in a high mortality from viral and fungal infections
[27,28]. Studies of ATG clearance in HSCT recipi-
ents, using ELISA for its detection, showed that signif-
icant levels of ATG can remain in the blood for up to
5 weeks posttransplantation [29,30]. Using different
commercial preparations and conditioning regimens,
as well as different timings and doses of ATG, may
contribute to the discrepancies in the reports from dif-
ferent centers.
G-CSF–mobilized bone marrow induces early
neutrophil engraftment with a reduced risk of
GVHD [31,32]. Ji et al [32] reported that using G-
CSF–primed haploidentical marrow grafts along with
combined sequential use of CSP, MMF, ATG, and
MTX provided an excellent alternative for the treat-
ment of high-risk hematologic malignancy in patients
without matched donors. The incidence of aGVHD
was surprisingly low, only 6.3% in G-CSF–primed
marrow transplants, compared with 33% in steady-
state marrow transplants [32]. Recently, the clinical
phenomenon has been confirmed by experimental
data; in vitro mixtures of G-PB and G-BM in different
proportions (G-PB:G-BM5 2:1, 1:1, and 1:2) has suc-
cessfully introduced T cell hyporesponsiveness and
polarization of T cells from Th1 to Th2 [33]. Under
the current BM/PB harvest protocol, G-BM was
harvested on day 0 after 4 days of G-CSF (target
dose, 15 mL/kg recipient weight), and G-PB was
harvested in a single leukapheresis on day 1 after
5 days of G-CSF therapy. In general, the number of
MNCs obtained from G-BM was 3.87 (1.19.52)
108/kg, and that obtained from G-PB was 3.795
(1.1712.1) 108/kg, with a BM:PB ratio of 1.006
(0.26.5) (results from analysis of our unpublished
data, n 5 98).G-BM also may add BM-derived mesenchymal
stromal cells (MSCs) to grafts. In vitro, MSCs inhibit
the proliferation of activated T cells and the formation
of cytotoxic T cells. In vivo, they appear to have anti-
inflammatory effects. Some previous results have shown
that MSC therapy can facilitate engraftment [34] and
decrease GVHD [35-37]. The affect of MSCs co-trans-
planted in allo-HSCT on the effect of graft versus leu-
kemia (GVL) response and the pathophysiologic
mechanism for decreasing graft versus host (GVH) re-
sponse remains under investigation [38-40]. Further-
more, the significance of the BM:PB ratio in the graft,
the immune characteristics of the T-cell subsets, den-
dritic cells, monocytes, natural killer cells (NKC), and
the cytokine profile introduced by combining G-mobi-
lized BM with G-PB need further investigation.
In our results, overall CD341 doses below those
reported by other centers may result from strict gating
for CD341 cell assay. Moreover, the dose of G-CSF
that we used (5 mg/kg/day) was significantly lower
than that reported by others (10-15 mg/kg/day)
[31,41,42]. Grafts mobilized by G-CSF have marked
tolerogenic properties. The immune characteristics
of the G-CSF–mobilized peripheral blood stem cells
(PBSCs) and BM may partially explain why the rela-
tively high CD31 cell dose in the transplant did not in-
crease the cumulative incidence of severe GVHD over
100 days or increase the incidence of cGVHD post-
transplantation. Our results correspond somewhat to
those of a recent report in which the 2 risk factors tra-
ditionally associated with aGVHD—age and the in-
fused doses of CD31, CD41, CD81, or CD341 cells
with PBSC grafts—did not significantly increase the
incidence of GVHD [43].
In conclusion, our data demonstrate that with the
currently available treatments, the dose of donor T cells
used in this protocol is rational and acceptable. Relatively
high numbers of MNCs and CD341, CD41, and CD81
cells and a significantly high CD31 cell dose contribute
to better posttransplantation survival and enhanced LFS,
resulting in part from a reduction in treatment-related
toxicity without an increase in severe GVHD.
ACKNOWLEDGMENTS
We are indebted to the patients and their families
and express our gratitude for their participation in
this study. We also acknowledge grants from the na-
tional ‘‘211 Project’’ (92000-242156014) and research
financial support from the Peking University EBM
group. Special thanks go to all of the staff members
at the Division of Hematopoietic Cell Transplanta-
tion, the HLA Lab, and the FCM Lab at Peking Uni-
versity and Beijing Dao-Pei Hospital for their
diligence and excellent work. We also thank Dr John
C. Herion for his critical reading and helpful revisions
to the manuscript and Dr Yan-Rong Liu for excellent
laboratory support by providing the FACS analysis.
CD31 Cell Dose and Disease Status after Haploidentical HCT 1523REFERENCES
1. Barnes DWH, Corp MJ, Loutit JF, et al. Treatment of murine
leukemia with x-rays and homologous bone marrow: prelimi-
nary communication. BMJ. 1956;2:626-627.
2. Appelbaum FR. Hematopoietic cell transplantation as a form of
immunotherapy. Int J Hematol. 2002;75:222-227.
3. Bortin MM, Gale RP, Kay HEM, et al. Bone marrow transplan-
tation for acute myelogenous leukemia. JAMA. 1983;249:
1166-1175.
4. Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-
related mortality and long-term graft function are significantly
influenced by cell dose in patients undergoing allogeneic mar-
row transplantation. Blood. 2002;100:3930-3934.
5. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of
donor CD31 cells is the most important factor for graft failure
after allogeneic transplantation of CD341 selected cells from
peripheral blood from HLA-identical siblings. Blood. 2001;97:
383-387.
6. Mohty M, Bagattini S, Chabannon C, et al. CD81 T-cell dose
affects development of acute graft-versus-host disease following
reduced-intensity conditioning allogeneic peripheral blood stem
cell transplantation. Exp Hematol. 2004;32:1097-1102.
7. Schuening F, Miller AD, Torok-Storb B, et al. Study on contri-
bution of genetically marked peripheral blood repopulating cells
to hematopoietic reconstitution after transplantation.HumGene
Ther. 1994;5:1523-1534.
8. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of
CD34 cell dose in blood cell transplantation for cancer therapy.
J Clin Oncol. 2000;18:1360-1377.
9. Aversa F, Martelli MM, Reisner Y. Use of stem cells from
mismatched related donors. Curr Opin Hematol. 1997;4:
419-422.
10. Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8
cell doses do not influence engraftment, graft-versus-host dis-
ease, or survival following myeloablative human leukocyte anti-
gen-identical peripheral blood allografting for hematologic
malignancies. Exp Hematol. 2005;33:279-285.
11. Handgretinger R, Schumm M, Lang P, et al. Transplantation of
megadoses of purified haploidentical stem cells. Ann N Y Acad
Sci. 1999;872:351-362.
12. Tabilio A, Falzetti F, Zei T, et al. Graft engineering for alloge-
neic haploidentical stem cell transplantation. Blood Cells Mol Dis.
2004;33:274-280.
13. Lu DP, Dong L, Wu T, et al. Conditioning including antithy-
mocyte globulin followed by un-manipulated HLA-mis-
matched/haploidentical blood and marrow transplantation can
achieve comparable outcomes to HLA-identical sibling trans-
plantation. Blood. 2006;107(8):3065-3073.
14. Drach J, Zhao S, Drach D, et al. Expression of MDR by normal
bone marrow cells and its implication for leukemia hematopoi-
esis. Leukemia Lymphoma. 1995;16:419-424.
15. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplanta-
tion. New Engl J Med. 1975;292:832-843, 895-902.
16. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine versus metho-
trexate for graft-versus-host disease prevention in patients given
marrow grafts for leukemia: long-term follow-up of three con-
trolled trials. Blood. 1988;71:293-298.
17. Glucksberg H, Fefer RS, Buckner CD, et al. Clinical manifesta-
tions of graft-versus-host disease in human recipients of marrow
from HLA-matched sibling donors. Transplantation. 1974;18:
295-304.18. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-
host disease and other late complications of bone marrow trans-
plantation. Semin Hematol. 1991;28:250-259.
19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man: a long-term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.
20. Ichinohe T, Uchiyama T, Shimazaki C, et al. Feasibility of
HLA-haploidentical hematopoietic stem cell transplantation
between noninherited maternal antigen (NIMA)-mismatched
family members linked with long-term fetomaternal microchi-
merism. Blood. 2004;104:3821-3828.
21. Van Rood JJ, Claas F. Noninherited maternal HLA antigens:
a proposal to elucidate their role in the immune response.
Hum Immunol. 2000;61:1390-1394.
22. Marks DI, Aversa F, Lazarus HM. Alternative donor trans-
plants for adult acute lymphoblastic leukaemia: a comparison
of the three major options. Bone Marrow Transplant. 2006;38:
467-475.
23. Aversa F, Terenzi A, Felicini R, et al. Haploidentical stem cell
transplantation for acute leukemia. Int J Hematol. 2002;76(Suppl
1):165-168.
24. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer
cell allorecognition of missing self in haploidentical hematopoi-
etic transplantation for acute myeloid leukemia: challenging its
predictive value. Blood. 2007;110:433-440.
25. Marks DI, Khattry N, Cummins M, et al. Haploidentical stem
cell transplantation for children with acute leukaemia. Br J Hae-
matol. 2006;134:196-201.
26. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immu-
notherapy with allodepleted donor T-cells improves immune
reconstitution after haploidentical stem cell transplantation.
Blood. 2006;108:1797-1808.
27. Naujokat C, Berges C, Fuchs D, et al. Antithymocyte globulins
suppress dendritic cell function by multiple mechanisms. Trans-
plantation. 2007;83:485-497.
28. Seidel MG, Fritsch G, Matthes-Martin S, et al. Antithymocyte
globulin pharmacokinetics in pediatric patients after hematopoi-
etic stem cell transplantation. J Pediatr Hematol Oncol. 2005;27:
532-536.
29. Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics
and pharmacodynamics of anti-thymocyte globulin in recipi-
ents of partially HLA-matched blood hematopoietic progen-
itor cell transplantation. Biol Blood Marrow Transplant. 2003;9:
460-471.
30. Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in
patients receiving thymoglobulin as part of conditioning before
unrelated donor stem cell transplantation. Haematologica. 2005;
90:869B.
31. Serody JS, Sparks SD, Lin Y, et al. Comparison of granulocyte
colony-stimulating factor (G-CSF)–mobilized peripheral blood
progenitor cells and G-CSF–stimulated bone marrow as a source
of stem cells in HLA-matched sibling transplantation. Biol Blood
Marrow Transplant. 2000;6:434-440.
32. Ji SQ, Chen HR, Wang HX, et al. G-CSF–primed haploiden-
tical marrow transplantation without ex vivo T cell depletion:
an excellent alternative for high-risk leukemia. Bone Marrow
Transplant. 2002;30:861-866.
33. Huang XJ, Chang JC, Zhao XY. Maintaining hyporesponsive-
ness and polarization potential of T cells after in vitro mixture
of G-CSF–mobilized peripheral blood grafts and G-CSF–
primed bone marrow grafts in different proportions. Transplant
Immunol. 2007;17:193-197.
1524 L. Dong et al.34. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation
of mesenchymal stem cells to enhance engraftment of hemato-
poietic stem cells. Leukemia. 2007;21:1733-1738.
35. Le Blanc K. Mesenchymal stromal cells: tissue repair and im-
mune modulation. Cytotherapy. 2006;8:559-561.
36. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem
cells for treatment of therapy-resistant graft-versus-host disease.
Transplantation. 2006;81:1390-1397.
37. Lazarus HM, Koc ON, Devine SM, et al. Co-transplanta-
tion of HLA-identical sibling culture-expanded mesenchymal
stem cells and hematopoietic stem cells in hematologic ma-
lignancy patients. Biology Blood Marrow Transplant. 2005;11:
389-398.
38. Aggarwal S, Pittenger MF. Human mesenchymal stem cells
modulate allogeneic immune cell responses. Blood. 2005;105:
1815-1822.
39. Chung NG, Jeong DC, Park SJ, et al. Co-transplantation of
marrow stromal cells may prevent lethal graft-versus-hostdisease in major histocompatibility complex mismatched murine
hematopoietic stem cell transplantation. Int J Hematol. 2004;80:
370-376.
40. Gieseke F, Schu¨tt B, Viebahn S, et al. Human multipotent mes-
enchymal stromal cells inhibit proliferation of PBMCs indepen-
dently of IFNgR1-signaling and IDO expression. Blood. 2007;
110(6):2197-2200.
41. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of al-
logeneic bone marrow transplantation using related donor
stimulated with G-CSF. Bone Marrow Transplant. 1997;20:
1033-1037.
42. Couban S, Messner HA, Andreou P, et al. Bone marrow mobi-
lized with granulocyte colony-stimulating factor in related allo-
geneic transplant recipients: a study of 29 patients. Biol Blood
Marrow Transplant. 2000;6:422-427.
43. Saliba RM, Lima MD, Giralt S, et al. Hyperacute GVHD: risk
factors, outcomes, and clinical implications. Blood. 2007;109:
2751-2758.
